Abstract
Despite their common use in treating psoriatic arthritis, there is little evidence supporting the use of conventional disease modifying agents such as methotrexate. Although treatment with inhibitors of TNF-α has brought significant benefit to certain patients with PsA, many do not respond. TNF-α inhibitors have also demonstrably failed to prevent new bone formation, a critical aspect to the changes in PsA that ultimately leads to joint destruction and disability. The identification of several new targets in PsA, and the advent of recently approved compounds inhibiting these targets, heralds a new dawn for PsA. The differential relevance of targets in rheumatoid arthritis and PsA underlines the need for a paradigm shift in how we name, describe and categorize rheumatic diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
